CN114504626A - She medicine formula for treating H-type hypertension phlegm-blood stasis syndrome - Google Patents
She medicine formula for treating H-type hypertension phlegm-blood stasis syndrome Download PDFInfo
- Publication number
- CN114504626A CN114504626A CN202210302512.8A CN202210302512A CN114504626A CN 114504626 A CN114504626 A CN 114504626A CN 202210302512 A CN202210302512 A CN 202210302512A CN 114504626 A CN114504626 A CN 114504626A
- Authority
- CN
- China
- Prior art keywords
- parts
- root
- phlegm
- syndrome
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 74
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 42
- 239000008280 blood Substances 0.000 title claims abstract description 31
- 206010062717 Increased upper airway secretion Diseases 0.000 title claims abstract description 27
- 208000026435 phlegm Diseases 0.000 title claims abstract description 27
- 206010041956 Stasis syndrome Diseases 0.000 title claims abstract description 21
- 208000005634 blind loop syndrome Diseases 0.000 title claims abstract description 21
- 210000004369 blood Anatomy 0.000 claims abstract description 27
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 24
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 17
- 235000015092 herbal tea Nutrition 0.000 claims abstract description 14
- 240000008866 Ziziphus nummularia Species 0.000 claims abstract description 13
- 241000427159 Achyranthes Species 0.000 claims abstract description 12
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims abstract description 12
- 241000545744 Hirudinea Species 0.000 claims abstract description 12
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims abstract description 12
- 241000157352 Uncaria Species 0.000 claims abstract description 12
- 229940107666 astragalus root Drugs 0.000 claims abstract description 10
- 244000209700 shan ge teng Species 0.000 claims abstract description 9
- 240000007594 Oryza sativa Species 0.000 claims abstract description 6
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 6
- 235000009566 rice Nutrition 0.000 claims abstract description 6
- 241001671204 Stemona Species 0.000 claims abstract description 5
- 241000736199 Paeonia Species 0.000 claims description 11
- 244000236658 Paeonia lactiflora Species 0.000 claims description 8
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims description 8
- 241000305492 Gastrodia Species 0.000 claims description 5
- 241000522190 Desmodium Species 0.000 claims description 4
- 241001106477 Paeoniaceae Species 0.000 claims description 4
- 241000219780 Pueraria Species 0.000 claims description 4
- 241001632409 Aralia elata Species 0.000 claims description 3
- 235000015888 Aralia elata Nutrition 0.000 claims description 3
- 241000208340 Araliaceae Species 0.000 claims description 3
- 241001061264 Astragalus Species 0.000 claims description 3
- 241000857907 Chimonanthus salicifolius Species 0.000 claims description 3
- 241000220485 Fabaceae Species 0.000 claims description 3
- 235000006533 astragalus Nutrition 0.000 claims description 3
- 210000004233 talus Anatomy 0.000 claims description 3
- 235000013616 tea Nutrition 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 6
- 240000007890 Leonurus cardiaca Species 0.000 claims 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims 1
- 235000009685 Crataegus X maligna Nutrition 0.000 claims 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims 1
- 235000009486 Crataegus bullatus Nutrition 0.000 claims 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims 1
- 235000009682 Crataegus limnophila Nutrition 0.000 claims 1
- 235000004423 Crataegus monogyna Nutrition 0.000 claims 1
- 240000000171 Crataegus monogyna Species 0.000 claims 1
- 235000002313 Crataegus paludosa Nutrition 0.000 claims 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims 1
- 241000885743 Melastoma dodecandrum Species 0.000 claims 1
- 241000219784 Sophora Species 0.000 claims 1
- 244000269722 Thea sinensis Species 0.000 claims 1
- 241001247821 Ziziphus Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 208000024891 symptom Diseases 0.000 abstract description 17
- 230000036772 blood pressure Effects 0.000 abstract description 10
- 210000001367 artery Anatomy 0.000 abstract description 4
- 230000002792 vascular Effects 0.000 abstract description 4
- 229940126673 western medicines Drugs 0.000 abstract description 4
- 244000170916 Paeonia officinalis Species 0.000 abstract 2
- 244000192528 Chrysanthemum parthenium Species 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 11
- 241000207925 Leonurus Species 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000001914 filtration Methods 0.000 description 8
- 230000003213 activating effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000035487 diastolic blood pressure Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- 241001312741 Gekko swinhonis Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 208000021328 arterial occlusion Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000013077 scoring method Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- 241001417516 Haemulidae Species 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 229960001770 atorvastatin calcium Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000021566 cold tea drink Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a she medicine formula for treating H-type hypertension phlegm and blood stasis syndrome, which comprises the following components in parts by weight: comprises 5-15 parts of Gaogou sticky rice, 5-15 parts of Gaogou grume, 5-15 parts of stemona, 15-25 parts of herbal tea, 25-35 parts of wild jujube, 25-35 parts of wild kudzu root, 2-4 parts of leech, 5-15 parts of cortex moutan, 5-15 parts of red peony root, 7-17 parts of motherwort, 7-17 parts of achyranthes root, 5-15 parts of rhizoma gastrodiae, 7-17 parts of uncaria, 7-17 parts of white paeony root, 5-15 parts of rhizoma acori graminei and 25-35 parts of astragalus root; the experimental results show that the total effective rates of the traditional Chinese medicine syndromes of the treatment group and the control group are respectively 75.0% and 90.6%, the traditional Chinese medicine syndrome curative effect of the treatment group is superior to that of the control group (P <0.05), and meanwhile, the treatment group is obviously superior to the control group (P <0.05) in the aspects of reducing the dynamic blood pressure of a patient and improving the traditional Chinese medicine syndrome integral, Hcy, baPWV and ABI levels. In conclusion, in the treatment of patients with the H-type hypertension and phlegm-blood stasis syndrome, the she medicine formula provided by the invention has an exact clinical treatment effect in combination with western medicines, can effectively improve the clinical symptoms of the patients, reduce the HCY level, obviously improve the vascular structure function, and improve the stiffness and elasticity of peripheral vascular arteries, and is worthy of clinical application.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a she medicine formula for treating H-type hypertension phlegm-stasis syndrome.
Background
The H-type hypertension refers to a special type of hypertension with human plasma homocysteine (Hcy) level more than or equal to 10umol/L and accompanied by essential hypertension, the Hcy and the hypertension are one of main risk factors causing arteriosclerosis, and the Hcy and the hypertension have strong synergistic effect and are mutually superposed to become the most important risk factor of cerebral apoplexy; in people with H-type hypertension, the incidence rate of cerebral apoplexy is increased by 11.7 times compared with that of normal hypertension patients, so that the H-type hypertension has higher harmfulness to cardiovascular and cerebrovascular diseases compared with the normal hypertension; however, in the prior art, no record is provided for a traditional Chinese medicine formula for treating the syndrome of intermingled phlegm and blood stasis of the H-type hypertension.
Disclosure of Invention
The invention aims to provide a she medicine formula for treating the syndrome of H-type hypertension with phlegm and blood stasis, and aims to solve the problems in the background technology.
In order to achieve the purpose, the invention provides the following technical scheme:
the she medicine formula for treating the H-type hypertension phlegm and blood stasis syndrome comprises the following components in parts by weight: comprises 5-15 parts of Gaogou sticky rice, 5-15 parts of Gaogou gruffs, 5-15 parts of stemona, 15-25 parts of herbal tea, 25-35 parts of wild jujube, 25-35 parts of wild kudzu root, 2-4 parts of leech, 5-15 parts of cortex moutan, 5-15 parts of red peony root, 7-17 parts of motherwort, 7-17 parts of achyranthes root, 5-15 parts of rhizoma gastrodiae, 7-17 parts of uncaria, 7-17 parts of white paeony root, 5-15 parts of rhizoma acori graminei and 25-35 parts of astragalus.
The formula comprises the following components in parts by weight: comprises 10 parts of gadogbane, 10 parts of gadoggrus, 10 parts of agaguo, 20 parts of herbal tea, 30 parts of wild jujube, 30 parts of wild pueraria root, 3 parts of leech, 10 parts of cortex moutan, 10 parts of red peony root, 12 parts of motherwort, 12 parts of achyranthes root, 10 parts of gastrodia tuber, 12 parts of uncaria, 12 parts of white peony root, 10 parts of grassleaf sweelflag rhizome and 30 parts of astragalus root.
The edible herbal tea is chimonanthus salicifolius.
The Geohu is Geohuang.
The Gekko Swinhonis is whole herb with root of Desmodium Lindl of Leguminosae.
The bird is dried root of Aralia elata seem of Araliaceae.
The fructus Choerospondiatis is fructus crataegi.
The preparation method of the she medicine formula for treating the H-type hypertension phlegm stasis syndrome comprises the following steps:
(1) according to the weight parts, 5-15 parts of Gagou sticky rice, 5-15 parts of Gagou grunt rice, 5-15 parts of Bainiao uninterrupted, 25-35 parts of wild jujube, 25-35 parts of wild kudzu root, 5-15 parts of cortex moutan, 5-15 parts of red peony root, 7-17 parts of motherwort, 7-17 parts of achyranthes root, 5-15 parts of gastrodia elata, 7-17 parts of white peony root and 25-35 parts of astragalus root.
Adding 10-15 times of water, decocting for 1-2 hr, filtering, and collecting the medicinal liquid.
(2) Adding 4-6 times of water into the dregs of the decoction in the step (1), decocting for 1h, adding 15-25 parts of herbal tea, 7-17 parts of uncaria and 5-15 parts of rhizoma acori graminei, decocting for 20 min, filtering, and mixing the liquid medicine with the liquid medicine in the step (1);
(3) concentrating the liquid medicine obtained in the step (2) until the relative density of a concentrated liquid phase is 1.20-1.40 and the pH value is 4.0-6.0;
(4) and (4) mixing 2-4 parts of leech powder with the Chinese medicinal liquid obtained in the step (3) to obtain the she medicine formula preparation for the H-type hypertension phlegm and blood stasis syndrome.
The preparation method of the she medicine formula for treating the H-type hypertension phlegm and blood stasis syndrome comprises the following steps:
(1) according to the weight portion, the medicine is prepared from 10 portions of Gadogbane, 10 portions of Gadoglu, 10 portions of white bird, 30 portions of wild jujube, 30 portions of wild kudzu root, 10 portions of cortex moutan, 10 portions of red peony root, 12 portions of motherwort, 12 portions of achyranthes root, 10 portions of rhizoma gastrodiae, 12 portions of white peony root and 30 portions of astragalus root.
Adding 10-15 times of water, decocting for 1-2 hr, filtering, and collecting the medicinal liquid.
(2) Adding 4-6 times of water into the dregs of the decoction obtained in the step (1), decocting for 1h, adding 20 parts of herbal tea, 12 parts of uncaria and 10 parts of rhizoma acori graminei, decocting for 20 min, filtering, and mixing the liquid medicine with the liquid medicine obtained in the step (1);
(3) concentrating the liquid medicine obtained in the step (2) until the relative density of a concentrated liquid phase is 1.20-1.40 and the pH value is 4.0-6.0;
(4) 3 parts of leech powder is mixed with the Chinese medicinal liquid in the step (3) to obtain the she medicine formula preparation for the H-type hypertension phlegm and blood stasis syndrome.
Adding 12 times of water by weight in the step (1) and decocting for 1 h.
Adding 4 times of water by weight in the step (2).
And (4) in the step (3), the relative density of the concentrated solution is 1.30.
And (3) the PH value in the step (3) is 5.1.
The beneficial technical effects of the invention compared with the prior art are that,
the experimental results show that the total effective rates of the traditional Chinese medicine syndromes of the treatment group and the control group are respectively 75.0% and 90.6%, the traditional Chinese medicine syndrome curative effect of the treatment group is superior to that of the control group (P <0.05), and meanwhile, the treatment group is obviously superior to the control group (P <0.05) in the aspects of reducing the dynamic blood pressure of a patient and improving the traditional Chinese medicine syndrome integral, Hcy, baPWV and ABI levels. In conclusion, in the treatment of patients with the H-type hypertension and phlegm-stasis syndrome, the she medicine formula provided by the invention has a definite clinical treatment effect by combining with western medicines, can effectively improve the clinical symptoms of the patients, reduce the HCY level, obviously improve the vascular structure function, prevent and treat arteriosclerosis, improve the arterial stiffness degree and elasticity function of peripheral blood vessels, prevent and treat arterial obstruction, and is worthy of clinical application.
Detailed Description
The present invention will be further described with reference to the following examples.
The she medicine formula for treating the H-type hypertension phlegm and blood stasis syndrome comprises the following components in parts by weight: comprises 5-15 parts of Gaogou sticky rice, 5-15 parts of Gaogou gruffs, 5-15 parts of stemona, 15-25 parts of herbal tea, 25-35 parts of wild jujube, 25-35 parts of wild kudzu root, 2-4 parts of leech, 5-15 parts of cortex moutan, 5-15 parts of red peony root, 7-17 parts of motherwort, 7-17 parts of achyranthes root, 5-15 parts of rhizoma gastrodiae, 7-17 parts of uncaria, 7-17 parts of white paeony root, 5-15 parts of rhizoma acori graminei and 25-35 parts of astragalus.
The formula comprises the following components in parts by weight: comprises 10 parts of gadogbane, 10 parts of gadoggrus, 10 parts of agaguo, 20 parts of herbal tea, 30 parts of wild jujube, 30 parts of wild pueraria root, 3 parts of leech, 10 parts of cortex moutan, 10 parts of red peony root, 12 parts of motherwort, 12 parts of achyranthes root, 10 parts of gastrodia tuber, 12 parts of uncaria, 12 parts of white peony root, 10 parts of grassleaf sweelflag rhizome and 30 parts of astragalus root.
The edible herbal tea is chimonanthus salicifolius.
The Geohu is Geohuang.
The Gekko Swinhonis is whole herb with root of Desmodium Picrorrhiza Linn of Desmodium of Leguminosae.
The bird is dried root of Aralia elata seem of Araliaceae.
The fructus Choerospondiatis is fructus crataegi.
The preparation method of the she medicine formula for treating the H-type hypertension phlegm stasis syndrome comprises the following steps:
(1) according to the weight portion, 5-15 portions of Gadogbane, 5-15 portions of Gadoglu, 5-15 portions of stemona, 25-35 portions of wild jujube, 25-35 portions of wild kudzu root, 5-15 portions of cortex moutan, 5-15 portions of red peony root, 7-17 portions of motherwort, 7-17 portions of achyranthes root, 5-15 portions of gastrodia tuber, 7-17 portions of white peony root and 25-35 portions of astragalus root.
Adding 10-15 times of water, decocting for 1-2 hr, filtering, and collecting the medicinal liquid.
(2) Adding 4-6 times of water into the dregs of the decoction in the step (1), decocting for 1h, adding 15-25 parts of herbal tea, 7-17 parts of uncaria and 5-15 parts of rhizoma acori graminei, decocting for 20 min, filtering, and mixing the liquid medicine with the liquid medicine in the step (1);
(3) concentrating the liquid medicine obtained in the step (2) until the relative density of a concentrated liquid phase is 1.20-1.40 and the pH value is 4.0-6.0;
(4) and (4) mixing 2-4 parts of leech powder with the Chinese medicinal liquid obtained in the step (3) to obtain the she medicine formula preparation for the H-type hypertension phlegm and blood stasis syndrome.
The preparation method of the she medicine formula for treating the H-type hypertension phlegm and blood stasis syndrome comprises the following steps:
(1) according to the weight portion, the medicine is prepared from 10 portions of Gadogbane, 10 portions of Gadoglu, 10 portions of white bird, 30 portions of wild jujube, 30 portions of wild kudzu root, 10 portions of cortex moutan, 10 portions of red peony root, 12 portions of motherwort, 12 portions of achyranthes root, 10 portions of rhizoma gastrodiae, 12 portions of white peony root and 30 portions of astragalus root.
Adding 10-15 times of water, decocting for 1-2 hr, filtering, and collecting the medicinal liquid.
(2) Adding 4-6 times of water into the dregs of the decoction obtained in the step (1), decocting for 1h, adding 20 parts of herbal tea, 12 parts of uncaria and 10 parts of rhizoma acori graminei, decocting for 20 min, filtering, and mixing the liquid medicine with the liquid medicine obtained in the step (1);
(3) concentrating the liquid medicine obtained in the step (2) until the relative density of a concentrated liquid phase is 1.20-1.40 and the pH value is 4.0-6.0;
(4) 3 parts of leech powder is mixed with the Chinese medicinal liquid in the step (3) to obtain the she medicine formula preparation for the H-type hypertension phlegm and blood stasis syndrome.
Adding 12 times of water by weight in the step (1) and decocting for 1 h.
And (3) adding 4 times of water by weight in the step (2).
And (4) in the step (3), the relative density of the concentrated solution is 1.30.
And (3) the PH value in the step (3) is 5.1.
The clinical experimental data are as follows:
1. case selection
Inclusion criteria were:
h-type hypertension (refer to the standard of H-type hypertension diagnosis and therapist consensus); the diagnosis of primary hypertension refers to '2020 ISH Global hypertension practice guideline' to diagnose as grade I hypertension;
② the syndrome differentiation of traditional Chinese medicine is the syndrome of phlegm-blood stasis (refer to the standard of the diagnosis and treatment guideline for common diseases in internal medicine of traditional Chinese medicine: the part of traditional Chinese medicine disease syndrome).
Exclusion criteria:
firstly, hypertension emergency and secondary hypertension;
② those accompanied with liver and kidney insufficiency, hematopoietic dysfunction, diabetes and thyroid dysfunction;
patients with severe organic heart disease in about 3 months, patients with stroke history in about 1 year and previous heart operation history;
fourthly, the patients can not take the medicine according to the requirement.
2. Sample(s)
64 cases were patients in the outpatient department and the residential department of the cardiovascular department of the hospital, and were randomly divided into a control group and a treatment group (32 cases each). In the control group, 16 cases were male and 16 cases were female; age 60-75 years, mean (68.9 ± 5.0) years; in the treatment group, 15 men and 17 women; the age was 60-75 years, with the mean (67.3. + -. 4.4) years. The difference between the two data sets was not statistically significant (P > 0.05) and was comparable.
3. Method of treatment
The two groups are treated by conventional western medicines, low salt and low fat, reasonable diet, smoking cessation limit wine, moderate exercise, and heart balance, and are orally administered in the form of valsartan capsule (Hezhou Siyao pharmaceutical Co., Ltd., Chinese medicine standard H20010824) at 80 mg/time for 1 time/day; amlodipine tablets (Zhejiang Kangkang pharmaceutical Co., Ltd., Chinese medicine standard H20066835) at 5 mg/time and 1 time/day; if the blood pressure is not ideal, add dihydrocodeine plus thiothium tablet (Shiqi pharmaceutical Co., Ltd., Chinese medicine standard H44023235) 12.5 mg/time, 1 time/day; atorvastatin calcium tablets (pfeiffer pharmaceutical limited, national drug standard H20051407), 10 mg/time, 1 time/night; folic acid tablet (Fujiangming Hua pharmaceutical Co., Ltd., national Standard H19993229), 0.4 mg/time, 1 time/day. The treatment course is 4 weeks.
The she medicine formula is added to a treatment group on the basis of a control group, and the she medicine formula comprises the following components in parts by weight: comprises 10 parts of gadogbane, 10 parts of gadoggrus, 10 parts of agaguo, 20 parts of herbal tea, 30 parts of wild jujube, 30 parts of wild pueraria root, 3 parts of leech, 10 parts of cortex moutan, 10 parts of red peony root, 12 parts of motherwort, 12 parts of achyranthes root, 10 parts of gastrodia tuber, 12 parts of uncaria, 12 parts of white peony root, 10 parts of grassleaf sweelflag rhizome and 30 parts of astragalus root. 1 dose per day, 400ml of the decoction is decocted in a preparation room of the hospital, and the decoction is taken in the morning and evening; the treatment course is 4 weeks.
4. Observation method
4.1 curative effect of traditional Chinese medicine symptoms: according to the assessment of symptom scores before and after treatment, the scores are drawn up according to the symptom scores in the New medicine (traditional Chinese medicine) treatment senile clinical research guiding principle. The analysis scoring method comprises the following steps: the main symptoms are respectively scored by semi-quantitative method, and the degree of the symptom is divided into none (0 point), light (2 points), medium (4 points) and heavy (6 points) according to the degree of the symptom, and the degree of the symptom is between two levels, and the degree of the symptom can be respectively counted into 1, 3 and 5 points.
Firstly, healing: clinical symptoms and physical signs of the traditional Chinese medicine disappear or basically disappear, and the syndrome integral is reduced by 95%;
secondly, effect is displayed: clinical symptoms and physical signs of the traditional Chinese medicine are obviously improved, and the syndrome integral is reduced by 70 to 95 percent;
③ effective: the clinical symptoms and physical signs of the traditional Chinese medicine are improved, and the syndrome integral is reduced by 30 to 70 percent;
fourthly, invalidation: the clinical symptoms and physical signs of the traditional Chinese medicine are not obviously improved or even aggravated, and the syndrome integral is reduced by less than 30 percent. The curative effect of the syndrome of traditional Chinese medicine is scored according to the degree by a 4-grade scoring method, and is observed and recorded for 1 time per week.
4.2 blood pressure, namely the evaluation of the hypertension curative effect in the guideline of clinical research on new Chinese medicines of the Ministry of health;
the method has the following advantages: the diastolic pressure is reduced by more than or equal to 10mmHg but is normal or the diastolic pressure is reduced by more than or equal to 20mmHg but is not normal;
secondly, the method is effective: diastolic blood pressure drops <10mmHg but is normal or drops by 10-19mmHg but is not normal;
(iii) invalid: the blood pressure is reduced or does not reach the standard.
4.324 hours ambulatory blood pressure: dioho dynamic blood pressure monitor (DMS-ABP type) measures the 24 hour mean systolic pressure (24hSBP), 24 hour mean diastolic pressure (24hDBP) before and after treatment of the patient.
4.4Hcy level: all patients are respectively detected before and after treatment, 3-5ml of elbow venous blood is collected in the early morning under an empty stomach, and Hcy is detected by adopting a circulatory enzyme method.
4.5 arteriosclerosis detection: the Oldham arteriosclerosis detector (model: HBP-8000) is used for measuring and calculating Ankle Brachial Index (ABI) and pulse wave velocity (baPWV) before and after treatment.
5 statistical methods
Statistical processing was performed using the sps 12.0 statistical software. The following test methods were used for the study according to the design and statistical requirements, respectively: firstly, carrying out average comparison on two samples designed in groups by using t test; second, the two sample rates are compared and checked by chi-square; checking the correlation coefficient by t. Ridit analysis was used for clinical grading comparisons. P <0.05 is significant, P >0.05 is no significant difference.
6 test results
6.1 in the treatment process of two groups of patients, the vital signs, the liver and kidney functions and the like do not have abnormal changes, adverse reactions do not occur, the patients can be matched with the medicine, and the test is completed as required without withdrawing the patients midway; only individual patients temporarily took a small amount of diuretics due to fluctuations in blood pressure.
6.2 comparison of the therapeutic effects of the syndromes of traditional Chinese medicine
The total effective rates of the control group and the treatment group are 75.0 percent and 90.6 percent respectively, the curative effect for improving the traditional Chinese medicine symptoms is that the treatment group is greater than the control group, and the traditional Chinese medicine syndrome curative effects between the groups are compared, and the difference has statistical significance (P <0.05), which is shown in table 1.
TABLE 1 two groups of clinical therapeutic effect comparison of TCM [ case (%) ]
| Group of | Number of examples | Cure of disease | Show effect | Is effective | Nullification | Total effective rate |
| Control group | 32 | 0 | 13(40.6) | 11(34.4) | 8(25.0) | 24(75.0) |
| Treatment group | 32 | 0 | 16(50.0) | 13(40.65) | 3(9.4) | 29(90.6) |
Note: p <0.05 compared to control group
6.324 h dynamic blood pressure
The post-treatment 24hSBP and 24hDBP in the two groups were reduced compared to the pre-treatment; the difference was statistically significant (P < 0.05); the differences between 24hSBP and 24hDBP were statistically significant (P <0.05) compared between groups before and after treatment, see Table 2.
TABLE 2 comparison of results for 24hSBP and 24hDBP before and after treatment (x + -s,)
Note that compared with the group before treatment, # P < 0.05; p <0.05 in comparison with control group
6.4Hcy level, baPWV and ABI treatment, the Hcy level, baPWV in both groups were reduced compared to before treatment, the difference was statistically significant (P <0.05) for the treated group below the control group. ABI increased higher in the post-treatment groups than before treatment, and there was a statistical difference (P <0.05) between the treatment groups and the control group, as shown in table 3.
TABLE 3 comparison of Hcy, baPWV, ABI results before and after treatment (x. + -.s)
Note that # P <0.05 compared to group before treatment; p <0.05 compared to control group
Discussion of 3
Poor control of H-type hypertension can cause or aggravate pathological changes of a blood vessel wall, the stiffness (elasticity) of an artery is changed earlier than the structure in the pathological changes of the blood vessel wall, no clinical symptoms exist in the early pathological changes of the blood vessel wall, the pulse wave conduction velocity (baPWV) is a gold index reflecting the stiffness (elasticity) of the middle large artery system, and the Ankle Brachial Index (ABI) is closely related to the stiffness (elasticity) of the artery.
In the she medicine formula, gao dog sticks (she), gao dog snores (she), hunger does not stop (she), cold tea drinks (she), wild jujubes (she) and wild kudzu roots (she) are used as main medicines to achieve the effects of activating blood and removing stasis, wherein the gao dog sticks to remove the stasis; gadoglu promotes blood circulation and removes blood stasis; the larch can not stop promoting blood circulation and dissipating stagnation; regulating qi and removing stagnation by eating cold tea (she); fructus Choerospondiatis (she) has effects of resolving food stagnation and promoting blood circulation, and radix Puerariae Lobatae (she) has effects of dredging and activating the channels and collaterals, and is matched with Hirudo for removing blood stasis and resolving food stagnation, cortex moutan and radix Paeoniae Rubra have effects of clearing heat, activating blood and removing blood stasis, and herba Leonuri and Achyranthis radix have effects of dredging collaterals, activating blood and removing blood stasis; rhizoma Gastrodiae and ramulus Uncariae cum uncis can calm liver, suppress yang hyperactivity, stop endogenous wind, and relieve convulsion, rhizoma Acori Graminei can eliminate turbid pathogen with aromatics, and remove turbid pathogen of blood stasis; the white paeony root is used for nourishing blood and softening liver, and the astragalus root is used for tonifying qi and strengthening body resistance, so that the medicines are used together for activating blood without damaging yin, removing food retention without damaging qi, and the whole formula has the effects of combining tonification and purgation, strengthening body resistance and eliminating evil, and has the functions of activating blood and removing food retention, and calming liver and eliminating turbid pathogen.
The experimental results show that the total effective rates of the traditional Chinese medicine syndromes of the treatment group and the control group are respectively 75.0% and 90.6%, the traditional Chinese medicine syndrome curative effect of the treatment group is superior to that of the control group (P <0.05), and meanwhile, the treatment group is obviously superior to the control group (P <0.05) in the aspects of reducing the dynamic blood pressure of a patient and improving the traditional Chinese medicine syndrome integral, Hcy, baPWV and ABI levels. In conclusion, in the treatment of patients with the H-type hypertension and phlegm-stasis syndrome, the she medicine formula provided by the invention has a definite clinical treatment effect by combining with western medicines, can effectively improve the clinical symptoms of the patients, reduce the HCY level, obviously improve the vascular structure function, prevent and treat arteriosclerosis, improve the arterial stiffness degree and elasticity function of peripheral blood vessels, prevent and treat arterial obstruction, and is worthy of clinical application.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that are within the spirit and principle of the present invention are intended to be included in the scope of the present invention.
Claims (7)
1. The she medicine formula for treating the H-type hypertension phlegm and blood stasis syndrome is characterized by comprising the following components in parts by weight: comprises 5-15 parts of Gaogou sticky rice, 5-15 parts of Gaogou gruffs, 5-15 parts of stemona, 15-25 parts of herbal tea, 25-35 parts of wild jujube, 25-35 parts of wild kudzu root, 2-4 parts of leech, 5-15 parts of cortex moutan, 5-15 parts of red peony root, 7-17 parts of motherwort, 7-17 parts of achyranthes root, 5-15 parts of rhizoma gastrodiae, 7-17 parts of uncaria, 7-17 parts of white paeony root, 5-15 parts of rhizoma acori graminei and 25-35 parts of astragalus.
2. The she-medicine formulation for treating hypertension H with syndrome of phlegm and blood stasis according to claim 1, wherein the formulation comprises, by weight: comprises 10 parts of gadogbane, 10 parts of gadoggrus, 10 parts of agaguo, 20 parts of herbal tea, 30 parts of wild jujube, 30 parts of wild pueraria root, 3 parts of leech, 10 parts of cortex moutan, 10 parts of red peony root, 12 parts of motherwort, 12 parts of achyranthes root, 10 parts of gastrodia tuber, 12 parts of uncaria, 12 parts of white peony root, 10 parts of grassleaf sweelflag rhizome and 30 parts of astragalus root.
3. The she medicinal formulation for treating hypertension H with syndrome of phlegm and blood stasis according to claim 1 or 2, wherein said herb tea is Chimonanthus salicifolius.
4. The she medicine composition for treating hypertension and phlegm-stasis syndrome type H according to claim 1 or 2, wherein the Gadoglu is Melastoma dodecandrum.
5. The she-medicine formulation for treating hypertension phlegm-stasis syndrome according to claim 1 or 2, wherein the gadogwood is the whole herb with root of sophora parviflora belonging to desmodium of leguminosae.
6. The she medicinal formulation for treating hypertension phlegm-stasis syndrome of type H according to claim 1 or 2, wherein the bird is a dry root of aralia elata of family araliaceae.
7. The she's medicine formulation for treating hypertension H with syndrome of phlegm and blood stasis according to claim 1 or 2, wherein the zizyphus mazakii is hawthorn.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210302512.8A CN114504626A (en) | 2022-03-24 | 2022-03-24 | She medicine formula for treating H-type hypertension phlegm-blood stasis syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210302512.8A CN114504626A (en) | 2022-03-24 | 2022-03-24 | She medicine formula for treating H-type hypertension phlegm-blood stasis syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114504626A true CN114504626A (en) | 2022-05-17 |
Family
ID=81555198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210302512.8A Pending CN114504626A (en) | 2022-03-24 | 2022-03-24 | She medicine formula for treating H-type hypertension phlegm-blood stasis syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114504626A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110179922A (en) * | 2019-06-04 | 2019-08-30 | 丽水市中医院 | A kind of the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription for the treatment of hypertension syndrome of blood stasis |
-
2022
- 2022-03-24 CN CN202210302512.8A patent/CN114504626A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110179922A (en) * | 2019-06-04 | 2019-08-30 | 丽水市中医院 | A kind of the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription for the treatment of hypertension syndrome of blood stasis |
Non-Patent Citations (3)
| Title |
|---|
| 潘铨等: "畲医活血消积方对H 型高血压左室肥厚的临床疗效及内质网应激的影响", 《中华全科医学》 * |
| 潘铨等: "畲药活血消积方治疗H型高血压左室肥厚血瘀证40例观察", 《浙江中医杂志》 * |
| 范蕾等: "12 种畲药的研究进展", 《中国药师》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022011880A1 (en) | Spleen strengthening traditional chinese medicine composition and application thereof | |
| WO2022021639A1 (en) | Traditional chinese medicine composition for invigorating spleen and activating yang, and use thereof | |
| CN110478452B (en) | Traditional Chinese medicine composition for treating gout and preparation method thereof | |
| CN1173726C (en) | Medicine for curing malignant turnor and its preparation method | |
| CN115252753A (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
| CN112138084B (en) | Traditional Chinese medicine composition for treating bronchiectasis qi-yin deficiency and phlegm-heat obstructing lung and application thereof | |
| CN111084820B (en) | Traditional Chinese medicine composition for treating chronic kidney disease malnutrition and preparation and application thereof | |
| CN114504626A (en) | She medicine formula for treating H-type hypertension phlegm-blood stasis syndrome | |
| Goto et al. | Clinical evaluation of the effect of daio (rhei rhizoma) on the progression of diabetic nephropathy with overt proteinuria | |
| CN103230552B (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN107823487B (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease and preparation method and application thereof | |
| CN108619427B (en) | Pain-relieving and acid-reducing herb tea for preventing and treating gouty arthritis | |
| CN105920371A (en) | Ganoderma lucidum compound preparation effective in lowering 'three highs' | |
| CN103768129B (en) | Drug composition for preventing or treating hypertension | |
| CN111135247A (en) | Traditional Chinese medicine for treating stage IV diabetic nephropathy | |
| CN116920047B (en) | Novel traditional Chinese medicine compound composition for treating myocardial injury related to coronavirus infection and preparation method thereof | |
| CN114617924B (en) | Composition for treating type 2 diabetes | |
| CN114917310B (en) | Traditional Chinese medicine for treating 3-5 stages of chronic kidney disease and preparation method thereof | |
| CN108403803B (en) | Chinese medicinal compound preparation for preventing and treating cardiovascular complications of diabetes | |
| CN115137785B (en) | Membranous kidney prescription for treating idiopathic membranous nephropathy | |
| CN112138105B (en) | Traditional Chinese medicine composition for treating bronchiectasis lung-spleen qi deficiency and phlegm-damp lung blocking syndrome and application thereof | |
| CN105943860A (en) | Medicine preparation for treating diabetes mellitus and preparation method thereof | |
| CN115381906A (en) | Traditional Chinese medicine composition for treating metabolic syndrome and preparation method and application thereof | |
| CN104940396B (en) | It is a kind of to reduce medicine of the Steroid-resistant nephrotic syndrome patient to Hormone refractory | |
| CN111150784A (en) | Pure Chinese herbal medicine powder for treating liver cirrhosis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220517 |